Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
22.69%
operating margin TTM
58.45%
revenue TTM
755.63 Million
revenue per share TTM
6.43$
valuation ratios | |
|---|---|
| pe ratio | 26.36 |
| peg ratio | -0.57 |
| price to book ratio | 171.11 |
| price to sales ratio | 5.98 |
| enterprise value multiple | 8.79 |
| price fair value | 171.11 |
profitability ratios | |
|---|---|
| gross profit margin | 81.95% |
| operating profit margin | 58.45% |
| pretax profit margin | 33.43% |
| net profit margin | 22.69% |
| return on assets | 12.55% |
| return on equity | 92.67% |
| return on capital employed | 34.76% |
liquidity ratios | |
|---|---|
| current ratio | 4.66 |
| quick ratio | 3.66 |
| cash ratio | 0.76 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 255.46 |
| operating cycle | 370.78 |
| days of payables outstanding | 30.25 |
| cash conversion cycle | 340.53 |
| receivables turnover | 3.16 |
| payables turnover | 12.07 |
| inventory turnover | 1.43 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | 45.03 |
| cash flow to debt ratio | 0.00 |
cash flow ratios | |
|---|---|
| free cash flow per share | 5.48 |
| cash per share | 1.21 |
| operating cash flow per share | 5.54 |
| free cash flow operating cash flow ratio | 0.99 |
| cash flow coverage ratios | 0.00 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 93.48 |
Frequently Asked Questions
When was the last time Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported earnings?
Halozyme Therapeutics, Inc. (HALO) published its most recent earnings results on 03-10-2025.
What is Halozyme Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s trailing twelve months ROE is 92.67%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Halozyme Therapeutics, Inc. (HALO) currently has a ROA of 12.55%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did HALO's net profit margin stand at?
HALO reported a profit margin of 22.69% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is HALO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.66 in the most recent quarter. The quick ratio stood at 3.66, with a Debt/Eq ratio of 0.00.